Direct and Indirect Support for Innovation

Economic theory emphasizes that the private sector often underinvests in research and development (R&D) due to challenges in capturing all benefits and financial constraints. Governments address this market failure by incentivizing private firms to bridge the gap between private and social returns on R&D. These incentives include direct instruments like R&D grants and contributions and indirect instruments like R&D tax credits. These measures aim to boost innovation and productivity, which are critical drivers of economic growth.

Some Data Highlights

Global R&D Investment

• UNESCO Institute for Statistics: Global spending on R&D was around $1.7 trillion in 2021, with government funding accounting for approximately 30% of this total.
• Country-Specific Investments: The United States leads with an R&D investment of $656 billion in 2021, representing about 3.1% of its GDP. China follows with $526 billion, equivalent to 2.4% of its GDP.

R&D Investment as a Percentage of GDP

• South Korea: Invests approximately 4.5% of its GDP in R&D, one of the highest in the world. This significant investment has fueled its leadership in technology sectors such as semiconductors and consumer electronics.
• Israel: With 4.9% of GDP dedicated to R&D, Israel has become a global innovation hub, particularly in cybersecurity and biotechnology.
• European Union: The EU aims to reach a target of 3% of GDP for R&D investment by 2030. As of 2021, the average R&D investment across EU member states was about 2.2% of GDP.

Private vs. Public R&D Funding

• United States: Private sector accounts for approximately 70% of total R&D funding, with significant contributions from industries such as pharmaceuticals, technology, and automotive.
• Japan: Private sector funding constitutes around 78% of total R&D expenditure, driven by major corporations like Toyota and Sony.
• Germany: The private sector contributes about 67% to R&D funding, with strong investments from the automotive and engineering industries.

Sector-Specific R&D Spending

• Pharmaceuticals: The global pharmaceutical industry spent over $190 billion on R&D in 2021. Leading companies like Pfizer and Roche each invest over $10 billion annually in R&D.
• Technology: In 2021, major tech companies such as Amazon, Alphabet (Google), and Microsoft collectively invested over $60 billion in R&D, focusing on areas like artificial intelligence, cloud computing, and hardware development.

Impact of R&D on Economic Growth

• Economic Studies: Research by the OECD indicates that a 1% increase in R&D spending can boost GDP growth by 0.61% over a period of time.
• Innovation and Productivity: A study by the European Commission found that countries with higher R&D investments experience higher rates of productivity growth, contributing to long-term economic stability and competitiveness.

Government Tools to Support Innovation

Governments use supply-push and demand-pull instruments to foster innovation. Supply-push instruments, which increase innovation activity supply, include direct tools (grants, loans) and indirect tools (tax credits, allowances). Demand-pull instruments increase demand for innovation through mechanisms like government procurement.

• Supply-Push Instruments:
  • Grants and Loans: The European Union’s Horizon 2020 program allocated €80 billion between 2014 and 2020 to support research and innovation.
  • Tax Credits: In the United States, the R&D Tax Credit was valued at $18 billion in 2020, offering substantial support to firms engaging in R&D.

• Demand-Pull Instruments:
  • Government Procurement: The U.S. Small Business Innovation Research (SBIR) program allocates over $2 billion annually in federal R&D funding to small businesses, driving innovation through government contracts.

Direct Support Advantages and Disadvantages

Direct support, such as grants, can precisely target market failures and barriers to innovation, offering flexibility to focus on projects with high social returns. However, it may crowd out private R&D investment, displace private sector investments, and suffer from administrative inefficiencies, information asymmetries, and political pressures.

Advantages

• Targeted Funding: Direct support allows governments to target specific sectors or technologies with high potential for social returns. For example, Germany’s High-Tech Strategy has focused on renewable energy, resulting in Germany becoming a global leader in this field.
• Flexibility: Direct funding can be adjusted to meet the changing needs of the innovation landscape. During the COVID-19 pandemic, many governments quickly redirected R&D funds to support vaccine development.

Disadvantages

• Crowding Out: A study by the National Bureau of Economic Research found that in some cases, public R&D funding can crowd out private investment, reducing overall efficiency.
• Administrative Burden: Managing and overseeing grant programs can be costly and complex, potentially leading to delays and inefficiencies.

Indirect Support Advantages and Disadvantages

Indirect support, like tax credits, is neutral across industries and firm sizes, easier to administer, and does not interfere with firms’ R&D strategies. However, it may not address specific market failures, favor short-term projects, and provide weaker spillover benefits.

Advantages

• Neutrality: Tax credits apply broadly across different sectors, encouraging a diverse range of innovations. In Canada, the Scientific Research and Experimental Development (SR&ED) tax incentive program provides over $3 billion annually to a wide array of industries.
• Ease of Administration: Tax credits are less complex to administer than direct grants, reducing administrative costs and allowing firms to allocate resources more efficiently.

Disadvantages

• Lack of Targeting: Indirect support may not effectively address specific market failures or prioritize high-impact projects. A report by the OECD highlighted that tax credits are less effective in driving radical innovation compared to direct funding.
• Short-Term Focus: Firms may prioritize projects with quicker returns to benefit from tax incentives, potentially neglecting long-term, high-risk R&D efforts.

Hijacking of Public Investment Results by Private Companies

A potential downside of public investment in R&D is that private companies may hijack the results for their own benefit, without adequately contributing to the public good. This occurs when firms leverage publicly funded research to develop profitable products while the societal benefits remain limited or underutilized. Example:

• Pharmaceutical Industry: A notable example is in the pharmaceutical industry. Governments often fund basic biomedical research that leads to the development of new drugs. Private companies can then license these publicly funded discoveries, develop commercial products, and secure patents. The high profits generated from these products are not always reinvested into further public research or used to reduce drug prices, thus limiting the broader social benefits.
• Drug Development Costs: The Tufts Center for the Study of Drug Development estimates that developing a new prescription drug costs $2.6 billion, with significant contributions from public funding in early-stage research.
• Public Funding Impact: The National Institutes of Health (NIH) in the United States provided $37 billion in funding in 2020, contributing to critical research that private firms later commercialize.
• High-Cost Drugs: Drugs like the cancer treatment Keytruda, initially developed through public research funding, are sold at high prices, making them inaccessible to many patients who indirectly funded their development through taxes.

Conclusion

Governments utilize both direct and indirect instruments to support R&D in the private sector. Direct instruments include grants and loans, while indirect instruments encompass tax credits and allowances. Both methods are crucial in stimulating R&D expenditures and positively impacting recipient firms’ performance. However, challenges like the hijacking of public investment results by private companies need to be addressed to ensure that societal benefits are maximized. The choice and balance of these instruments depend on the specific market failures being addressed and the public policy objectives.

Final Thoughts

• Balancing Instruments: Policymakers must carefully balance direct and indirect support mechanisms to optimize the impact of public R&D investments.
• Addressing Hijacking: Implementing policies that ensure a fair distribution of benefits from publicly funded research, such as profit-sharing agreements or reinvestment requirements, can mitigate the risk of hijacking.
• Future Trends: As global challenges like climate change and pandemics emerge, the role of public R&D funding in driving innovation for the public good will become increasingly vital.

By understanding and addressing the nuances of direct and indirect support for innovation, governments can better foster environments that promote sustained economic growth and societal well-being.